Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prelude Therapeutics Inc

0.8605
-0.0006-0.07%
Post-market: 0.86050.00000.00%18:58 EDT
Volume:108.74K
Turnover:96.56K
Market Cap:48.58M
PE:-0.51
High:0.9485
Open:0.8787
Low:0.8530
Close:0.8611
Loading ...

Prelude Therapeutics Appoints Paul Scherer as Director

TIPRANKS
·
14 Jun

Prelude Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
14 Jun

Prelude Therapeutics Inc. to Participate in Jefferies and Goldman Sachs Global Healthcare Conferences

Reuters
·
02 Jun

Prelude Therapeutics (PRLD) Receives a Sell from Barclays

TIPRANKS
·
07 May

Prelude Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

BRIEF-Prelude Therapeutics Q1 EPS USD -0.42

Reuters
·
07 May

Prelude Therapeutics Q1 EPS USD -0.42

THOMSON REUTERS
·
07 May

Prelude Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Reuters
·
02 May

Prelude Therapeutics to Participate in Citizens Life Sciences Conference in New York

Reuters
·
01 May

Prelude Announces Presentations at 2025 AACR Annual Meeting

GlobeNewswire
·
26 Apr

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know

Zacks
·
11 Apr

Prelude Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
08 Apr

3 Promising Penny Stocks With Market Caps Up To $300M

Simply Wall St.
·
01 Apr

Prelude Therapeutics Founder Acquires 28% More Stock

Simply Wall St.
·
29 Mar

Prelude Therapeutics CEO Makes Bold Stock Purchase!

TIPRANKS
·
19 Mar

Prelude Therapeutics Reports 2024 Financial Results

TIPRANKS
·
11 Mar

Prelude Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
11 Mar

Prelude Therapeutics FY Sales $7.000M Beat $2.000M Estimate

Benzinga
·
10 Mar

Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)

TIPRANKS
·
10 Mar

Prelude Therapeutics sees cash runway into 2Q26

TIPRANKS
·
10 Mar